Ki Tua Fund
VC Fund
Ki Tua Fund is a VC fund focused on Biotechnology and Life Science. Ki Tua Fund invests in, partners, and works with innovative start-ups, to accelerate and scale disruptive solutions. The firm is combining science, nutrition, and technology to impact health positively.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Ki Tua Fund invests in
Stages Ki Tua Fund invests in
Countries Ki Tua Fund invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Life Science 2 (40%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Sustainability 1 (20%)
Stage
- Seed 1 (20%)
- Series A 1 (20%)
- Series B 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kanvas Biosciences
|
Kanvas Biosciences developed cutting-edge imaging technology for microbial detection, providing unmatched speed, breadth, and adaptability. Kanvas aims to transform microbial research and infectious disease diagnostics through innovative imaging technology of the next generation. | $48M / Series A / May 05, 2026 | |
Fermeate
|
Fermeate provides photomolecular fermentation technology to increase sustainability and efficiency in the biomanufacturing industry. | $2.5M / Seed / Apr 27, 2026 | |
BioLumic
|
BioLumic develops light signals that activate plant growth and unlock the natural genetic potential of crops. The company's photogenics platform leverages innovation in plant science, light technology and genetic insights. Demonstrated results include higher yield, improved vigor, increased disease and pest resistance, and improvements incrops composition. These results have been across a variety of seeds and seedling: soybean, cannabis and vegetable and fruit crops. It is a clean technology that does not require the use of chemicals or amendments. BioLumic is a private company and was founded in 2013. | $8.3M / Series B / Apr 22, 2025 | |
|
Kanvas Biosciences
|
Kanvas Biosciences developed cutting-edge imaging technology for microbial detection, providing unmatched speed, breadth, and adaptability. Kanvas aims to transform microbial research and infectious disease diagnostics through innovative imaging technology of the next generation. | $12.5M / Series A / Jul 01, 2024 | |
Prolific Machines
|
Prolific Machines is a biotech company developing cell technologies to redefine how cells are produced for a sustainable and healthy future. It combines cutting-edge technologies to enable cell production at a new scale. The company was founded in 2020 and is based in San Francisco, California. | $55M / Series B / Jun 06, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ki Tua Fund invest in?
Ki Tua Fund invests primarily in Biotechnology, Life Science and Health Care startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ki Tua Fund last invest?
The most recent investment recorded for Ki Tua Fund closed in May 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
